Inactive

The Centers for Disease Control and Prevention intends to award one sole source firm fixed price contract modification under contract 75D30123D16727 to GlaxoSmithKline, LLC (GSK) for the addition of t... The Centers for Disease Control and Prevention intends to award one sole source firm fixed price contract modification under contract 75D30123D16727 to GlaxoSmithKline, LLC (GSK) for the addition of the Advisory Committee for Immunization Practices (ACIP) recommended Arexvy vaccine. The National Center for Immunization and Respiratory Diseases (NCIRD) awarded multiple indefinite delivery, indefinite quantity (IDIQ) one-year contracts for the purchase of standard commercial adult vaccines, manufactured under a current establishment and product license issued by the U.S. Food and Drug Administration (FDA). The vaccines awarded under these contracts will be purchased for NCIRD's immunization awardees (the fifty state health departments, several large city program and current and former U.S. Territories) to support immunization programs as provided under Section 317(j) of the Public Health Service Act. Orders for the vaccines on these contracts are ordered through the NCIRD electronic vaccine ordering system. The initial contracts, awarded in June 2023, were established to support public sector ACIP recommended routine vaccinations for adults. This new respiratory syncytial virus (RSV) vaccine was not licensed at the time the CDC solicited for its adult vaccine contracts. The GSK contract will be modified to support purchase of Arexvy for prevention of RSV in adults following CDC's ACIP approval on June 21, 2023. GSK received an FDA-approved license for Arexvy, which is licensed for the prevention of RSV in adults. The CDC's current contract with GSK will be modified to include a sufficient quantity of doses required to support the purchase of Arexvy. This contract action is for supplies or services for which the Government intends to solicit and negotiate with only one source under the authority of FAR 6.302-1 and 41U.S.C. 3304(a)(l). Interested persons may identify their interest and capability to respond to the requirement or submit proposals. This notice of intent is not a request for competitive quotations; however, all quotations/responses received within seven (7) days of the issuance of this notice will be considered by the Government. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. Any quotation/response should be emailed to Brian Swann at qty0@cdc.gov by 5:00 PM ET on September 15, 2023.